top of page
RT Banners (1).png

We invite you to engage in an interactive nintely minute roundtable led by EverythingALS consortia of Pharma partners, sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.

 

Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in EverythingALS research, which will be expanded to include analyzing data from wearables and smartphones.

  

As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.         

This is an invite only event.

Hosts & Speakers 

  • Twitter
  • LinkedIn
  • icons8-link-60
  • LinkedIn
  • LinkedIn
    • LinkedIn
    • icons8-link-60
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn

    Agenda

    Friday June 25th, 2025

    12:30 - 2:00 PM ET   I   9:30 - 11:00 AM PT

    10 minutes

    10 minutes

    10 minutes

    20 minutes

    10 minutes

    10 minutes

    Highlights and Announcements

    ​​Indu Navar, Founder & CEO, EverythingALS

    Welcome the new Consortia members

    Lars Ittner, MD.  Founder and Chief Medical Officer, Celosia Therapeutics

    Olga Uspenskaya, MD, PhD. Chief Medical Officer, VectorY Therapeutics

    Keynote: "It broke my heart, because I loved what I do!”

    Monica Martinez, Person Living with ALS

          ​

    Listener Effort as a Marker of Dysarthria Progression in ALS.

    FDA Drug Development Tool (DDT) CDER - Context of Use and Next Steps

    Dr. James Berry, Chief, Division of ALS and MND, Mass General Brigham

    Brendan O'Leary, Medical and Digital Health, Regulation, and Policy 

    Henk Schuring, Chief Regulatory and Commercialization Officer, Prilenia

    Research Recognition

    Research and Data Science Team, EverythingALS

    Collaboration Highlights

    Kelly Norel, PhD, Staff Research Scientist, Digital Health, IBM

    Julian Peller, Head of Data Science, EverythingALS

    END OPEN SESSION

    CONSORTIA MEMBERS' BREAKOUT

    1:40-2:00 PM ET

    Closed session

    Aug 10 & 11th Consortia Summit: Agenda Finalization

    Agenda

    Participants

     

    © 2025 by EverythingALS

    EverythingALS is part of Peter Cohen Foundation, a non-profit 501(c)(3), United States. EIN 84-3055901 

    Email: info@everythingals.org

    bottom of page